Finasteride vs Spironolactone: Side-Effect Profile Head-to-Head

How Each Drug Works, and Why the Mechanisms Drive Different Side Effects

Finasteride and spironolactone both reduce androgenic activity, but they do so at completely different points in the hormone pathway. That distinction explains why their adverse-event profiles look so different despite their shared goal.

Finasteride: Targeting DHT Synthesis

Finasteride is a competitive inhibitor of type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT) in the prostate, scalp, and skin 1. At 1 mg daily, it reduces serum DHT by approximately 65 to 70% within two weeks of starting therapy. Because DHT is a more potent androgen than testosterone, this reduction meaningfully slows follicle miniaturization in androgenetic alopecia (AGA).

The 5 mg finasteride formulation (Proscar) is approved for benign prostatic hyperplasia (BPH), while the 1 mg formulation (Propecia) is approved specifically for male-pattern hair loss 2.

Spironolactone: Blocking the Androgen Receptor

Spironolactone does not reduce androgen production. It binds androgen receptors directly, preventing testosterone and DHT from activating them 3. It also blocks mineralocorticoid receptors, which is why it causes potassium retention and diuresis as off-target effects. Doses for hormonal acne and female-pattern hair loss typically range from 50 mg to 200 mg daily, with most clinicians starting at 50 to 100 mg and titrating based on response and tolerability.

Because spironolactone affects both androgen receptors and aldosterone signaling simultaneously, its side-effect list covers two distinct physiological systems in ways finasteride does not.

Side-Effect Profile: Finasteride

The side effects of finasteride are concentrated in sexual function and, to a lesser degree, mood. The drug's action on DHT also affects neurosteroid synthesis, which likely underpins the mood and cognitive complaints some users report.

Sexual Adverse Events

The key Kaufman et al. Trial (J Am Acad Dermatol, 1998; N=1,553 men) showed sexual adverse events including decreased libido, erectile dysfunction, and reduced ejaculate volume in approximately 3.8% of finasteride-treated men at 1 mg daily over two years, compared with 2.1% in the placebo group 1. The absolute risk difference is modest, but these events carry real quality-of-life weight for affected individuals.

The FDA updated finasteride's label in 2012 to include libido disorders, ejaculation disorders, and orgasm disorders that may persist after stopping the drug 2.

Post-Finasteride Syndrome

A subset of men report persistent sexual dysfunction, depression, and cognitive symptoms that continue or even worsen after discontinuing finasteride. This cluster has been named post-finasteride syndrome (PFS). The Post-Finasteride Syndrome Foundation estimates prevalence is difficult to quantify, and the condition remains under active mechanistic investigation, with hypotheses centering on altered neurosteroid ratios and epigenetic changes 4.

Clinicians should discuss PFS risk explicitly with patients before prescribing, even though causation has not been definitively established.

Mood and Cognitive Effects

Depression and, rarely, suicidal ideation have been reported in post-marketing surveillance. A 2017 study published in JAMA Internal Medicine found that men taking 5-alpha reductase inhibitors had a statistically elevated risk of depression and self-harm during the first 18 months of use 5. The signal was present at both 1 mg and 5 mg doses.

Gynecomastia

Tender breast tissue develops in roughly 0.4% of men on 1 mg finasteride. The mechanism is indirect: lowering DHT shifts the testosterone-to-estrogen ratio slightly toward estrogen activity at breast tissue receptors 2.

PSA and Prostate Cancer Screening

Finasteride reduces prostate-specific antigen (PSA) by approximately 50% within six months. Any clinician ordering PSA for cancer screening in a man taking finasteride must double the measured value to get a clinically meaningful estimate 6.

Side-Effect Profile: Spironolactone

Spironolactone's adverse events break into two categories: those from aldosterone blockade (electrolyte and blood pressure effects) and those from androgen receptor blockade in hormone-sensitive tissues.

Electrolyte and Renal Effects

Blocking aldosterone causes potassium retention. Hyperkalemia is the most medically serious risk of spironolactone. In otherwise healthy young women taking 50 to 100 mg daily for acne, the absolute risk of clinically significant hyperkalemia is low but non-zero 7. Risk rises substantially in patients who also take ACE inhibitors, angiotensin receptor blockers, potassium supplements, or who have chronic kidney disease.

Blood pressure drops meaningfully in some patients. This can be a feature (spironolactone is approved for resistant hypertension) or an adverse event, depending on baseline blood pressure. Dizziness and near-syncope from orthostatic hypotension occur at higher doses.

Polyuria and polydipsia are common, particularly in the first few weeks, because aldosterone blockade increases urine output before the body compensates.

Menstrual Irregularity and Breast Tenderness

Spironolactone disrupts menstrual cycling in a significant proportion of women. Irregular bleeding, spotting between periods, and changes in cycle length are reported by 10 to 20% of users at doses above 100 mg 8. Breast tenderness is also common and appears to be dose-dependent.

For women not using reliable contraception, these menstrual changes complicate cycle tracking. Many clinicians co-prescribe a combined oral contraceptive, which both controls menstrual irregularity and provides contraception against the teratogenic risk.

Feminizing Effects in Men

Spironolactone is rarely used in men for acne or hair loss because its anti-androgen effects cause gynecomastia and sexual dysfunction at the doses required for efficacy. Gynecomastia rates in men taking spironolactone for heart failure (doses of 25 to 50 mg) approach 9% 9. At the 100 to 200 mg doses needed for dermatological benefit, this rate would likely be higher.

Gastrointestinal Symptoms

Nausea, vomiting, and abdominal cramping occur in a minority of patients, typically dose-dependent. Taking spironolactone with food reduces GI complaints for most users.

Head-to-Head Comparison Table

No randomized controlled trial has directly compared finasteride and spironolactone for the same indication with side effects as a primary endpoint. The table below synthesizes data from the individual drug trials.

| Side Effect | Finasteride 1 mg (men) | Spironolactone 50 to 200 mg (women) | |---|---|---| | Sexual dysfunction | 3.8% vs. 2.1% placebo [1] | Rare at therapeutic doses in women | | Gynecomastia/breast tenderness | ~0.4% | Common, dose-dependent | | Menstrual irregularity | Not applicable | 10 to 20% at doses >100 mg [8] | | Hyperkalemia | Not a recognized risk | Risk increases with CKD or interacting drugs [7] | | Hypotension | Not a recognized risk | Dose-dependent, especially at >100 mg | | Depression/mood changes | Signal in pharmacovigilance data [5] | Not a recognized class effect | | Persistent effects after stopping | Reported (PFS) | Not reported | | Teratogenicity | Yes, Category X | Yes, feminization of male fetuses | | Routine lab monitoring | Not required | Potassium and renal function recommended |

Who Should Take Which Drug

The patient's sex, the target condition, and comorbidities determine which drug is appropriate. Finasteride and spironolactone are not interchangeable.

Finasteride Is the Standard First-Line Agent for Men With AGA

Finasteride 1 mg daily remains the only FDA-approved oral medication for male androgenetic alopecia. The Kaufman et al. Trial demonstrated statistically significant increases in hair count and patient-rated improvement scores at two years, with sustained benefit extending to five years in a subset of trial participants 1. Men who tolerate the drug well can expect a clinically meaningful slowing of hair loss and, in many cases, partial regrowth.

Spironolactone is not a viable alternative for men because the anti-androgenic dose needed for hair benefit causes feminizing side effects that are unacceptable to most male patients.

Spironolactone Is Preferred in Women With Hormonal Acne or Female-Pattern Hair Loss

The Layton et al. Review (Br J Dermatol, 2017) evaluated spironolactone at 50 to 200 mg daily in adult women with hormonal acne and reported meaningful reductions in inflammatory lesion counts, with a safety profile appropriate for long-term use in healthy premenopausal women 3. The American Academy of Dermatology recognizes spironolactone as an appropriate agent for women who fail or cannot tolerate systemic antibiotics for acne.

Finasteride is used off-label in women for female-pattern hair loss (FPHL) at doses of 1 to 2.5 mg daily, though the FDA has not approved it for this indication. The teratogenic risk makes it a poor choice in women of reproductive potential without highly reliable contraception.

A Simple Clinical Decision Framework

The following three-question framework helps clinicians choose between these two agents:

1. Is the patient male? Finasteride is the default oral agent for AGA. Spironolactone is contraindicated in practice due to feminizing effects.
2. Is the patient a premenopausal woman with hormonal acne and/or FPHL? Spironolactone 50 to 100 mg daily is the first consideration, with co-prescribed contraception.
3. Does the patient have CKD, take ACE inhibitors or ARBs, or have baseline hyperkalemia? If yes, spironolactone carries a substantially elevated electrolyte risk and finasteride or topical alternatives should be prioritized.

Monitoring Protocols for Each Drug

Monitoring needs differ substantially between these two agents, which has practical implications for patient burden and prescribing logistics.

Finasteride Monitoring

No routine laboratory monitoring is required for healthy adults taking finasteride 1 mg for AGA. Clinicians should document a baseline discussion of sexual side effects, note any mood changes at follow-up visits, and remind patients to disclose finasteride use before PSA testing. The Prostate Cancer Prevention Trial (N=18,882) found that finasteride 5 mg reduced overall prostate cancer incidence but was associated with a higher proportion of high-grade tumors in a subset of cases, a finding that remains under ongoing discussion 6.

Spironolactone Monitoring

The Endocrine Society and multiple dermatology consensus guidelines recommend checking serum potassium and basic metabolic panel at baseline, then at 4 to 8 weeks after initiation or any dose increase, and annually thereafter in stable, healthy women 10. Blood pressure should be checked at each visit for the first three months.

A 2015 retrospective analysis published in JAMA Dermatology (N=974 young women taking spironolactone for acne) found no cases of clinically significant hyperkalemia, prompting some clinicians to question whether routine potassium monitoring is necessary in healthy women under 45 with no comorbidities 7. The Endocrine Society's 2018 clinical practice guideline on hormonal evaluation of hirsutism still recommends baseline and periodic potassium checks 10.

Pregnancy, Contraception, and Teratogenicity

Both drugs require a pregnancy warning, but for different biological reasons.

Finasteride is FDA Pregnancy Category X. Even skin contact with crushed tablets by a pregnant woman could theoretically transfer drug through mucous membranes; the prescribing information advises that women who are pregnant or may become pregnant should not handle broken finasteride tablets 2. Male fetuses exposed to finasteride in utero are at risk of genital abnormalities because DHT is required for normal male external genitalia development.

Spironolactone has not been assigned a formal FDA pregnancy letter category under the old system, but its prescribing information includes a warning about feminization of male rat fetuses at high doses. The American College of Obstetricians and Gynecologists recommends that spironolactone be discontinued before attempting conception 11. Most prescribers require co-prescription of a combined oral contraceptive or a confirmed non-fertile state before initiating spironolactone in women of reproductive age.

Can You Switch From Finasteride to Spironolactone?

Switching is biologically straightforward in women but is rarely done in men for the reasons described above. In a woman who has been taking finasteride off-label for FPHL and is experiencing inadequate response or side effects, transition to spironolactone 50 to 100 mg daily is a logical next step. No washout period is required; the mechanisms do not overlap in a pharmacokinetically problematic way.

Men switching from finasteride due to sexual side effects should be counseled that spironolactone is not an appropriate replacement for AGA because it causes its own set of androgenic and hormonal side effects at anti-androgenic doses. Topical minoxidil, low-level laser therapy, or a referral for hair transplantation may be more appropriate alternatives for men who cannot tolerate finasteride.

For sexual side effects specifically, some clinicians reduce the finasteride dose to 0.5 mg every other day as an interim step before full discontinuation, though pharmacokinetic data supporting dose reduction as a side-effect mitigation strategy are limited.

The Acne Angle: Spironolactone Wins for Women, Finasteride Has Limited Data

Spironolactone has a clear evidence base for hormonal acne in adult women. The Layton et al. Review synthesized multiple cohort studies and case series showing 50 to 200 mg daily produces clinically meaningful reductions in inflammatory and non-inflammatory lesion counts, with response typically visible by 8 to 12 weeks 3. The American Academy of Dermatology 2016 acne guidelines list spironolactone as a recommended adjunctive therapy for adult female patients with hormonal acne patterns 12.

Finasteride's role in acne is much less established. A small number of case reports and one open-label pilot study have explored its use in women with hyperandrogenic acne, but no adequately powered randomized trial has been published. Finasteride does not appear in major acne treatment guidelines as a recommended agent.

Drug Interactions Worth Knowing

Spironolactone interacts with a broader set of drug classes than finasteride.

Combining spironolactone with ACE inhibitors (e.g., lisinopril), angiotensin receptor blockers (e.g., losartan), potassium-sparing diuretics, or NSAIDs used chronically raises hyperkalemia risk meaningfully 9. Lithium clearance is reduced by spironolactone, raising lithium levels in patients on both drugs. Digoxin concentrations may increase when spironolactone is started or the dose is changed.

Finasteride has a narrower interaction profile. CYP3A4 inducers like rifampin may reduce finasteride plasma levels modestly, but no clinically significant drug interactions have been identified at the 1 mg dose in standard prescribing practice 2.

Long-Term Safety: What Five-Plus Years of Data Show

Long-term data on finasteride come largely from the AGA approval trials and the BPH database. Five-year data from the Kaufman et al. Extension showed that sexual adverse events did not worsen over time and that some early reporters experienced spontaneous resolution even while continuing the drug 1.

Long-term spironolactone data in dermatology patients are thinner. The largest retrospective cohort in dermatology was the 2015 JAMA Dermatology analysis (N=974), which tracked women for a median follow-up of 16 months and found the drug was generally well tolerated without serious electrolyte events in the healthy young cohort 7. Cardiovascular long-term safety data come from the heart failure literature, where spironolactone 25 to 50 mg in the RALES trial (N=1,663) showed survival benefit in severe heart failure but also a 10% rate of gynecomastia or breast pain in men 9.